Kaplan-Meier curves for OS and EFS according to genotypes with statistical significance in univariate analysis. (A-B) The median OS and EFS of patients with or without CEBPA mutations (CEBPAm⁺ or CEBPAm⁻) were 21.0 ± 5.8 months (mo) and 12.0 ± 1.5 mo (P = .002), 11.0 ± 5.1 mo, and 5.0 ± 0.5 mo (P = .004), respectively. (C-D) The median OS and EFS of patients with biallelic or monoallelic CEBPA mutations were not reached (NR) and 10.0 ± 1.6 mo (P < .001), and NR and 3.0 ± 0.7 mo (P = .001), compared with wild-type CEBPA patients. (E-F) The median OS and EFS of patients with or without DNMT3A mutations (DNMT3Am⁺ or DNMT3Am⁻) were 7.0 ± 2.1 mo and 18.0 ± 2.3 mo (P < .001), 3.0 ± 0.3 mo and 8.0 ± 1.2 mo (P = .001), respectively. (G-H) The median OS and EFS of patients with or without MLL abnormalities (MLLm⁺ or MLLm⁻) were 8.0 ± 2.2 mo and 17.0 ± 2.4 mo (P < .001), 3.0 ± 0.2 mo and 8.0 ± 1.4 mo (P < .001), respectively. (I-J) The median OS and EFS of patients with or without N-RAS mutations (N-RASm⁺ or N-RASm⁻) were 10.0 ± 4.2 mo and 17.0 ± 2.1 mo (P = .084), 3.0 ± 0.3 mo and 8.0 ± 1.3 mo (P = .006), respectively. (K-L) The median OS and EFS of patients with NPM1 mutation but no DNMT3A mutation (NPM1m⁺/DNMT3Am⁻) were NR and 34.0 mo, whereas NPM1 mutation cases with DNMT3A mutations (NPM1m⁺/DNMT3Am⁺) had inferior OS (7.0 ± 3.4 mo, P < .001) and EFS (3.0 ± 0.6 mo, P = .002).